Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 20k
22 November 2017
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-006236/2017

In March 2017, the Commission launched a European Reference Network for paediatric cancer (PaedCan-ERN)(1) within the framework of Directive 2011/24/EU on patients' rights in cross-border healthcare(2). This European Reference Network will help to reduce inequalities in childhood cancer survival by providing high quality, accessible and cost-effective cross-border healthcare to children and adolescents with cancer, regardless of where they live. To make specialised expertise for live-saving paediatric oncology treatments available to patients across Europe, the ERN PaedCan will create a roadmap of healthcare centres that are renowned worldwide for their expertise in treating paediatric malignancies.

The PaedCan ERN will also implement eHealth technologies and improve interoperability across different institutions (e.g. via a virtual paediatric oncology tumour board network to share expertise and advice). It will also help young patients and their families make informed choices by providing clear information regarding access, quality and safety for treatments received in another EU country.

The Commission is also in the process of establishing a new mechanism for transferring best practices between EU Member States. A new steering group on health promotion, disease prevention and management of non-communicable diseases will identify best practices from all areas of healthcare and public health for implementation in interested Member States.


Legal notice